Aileron Therapeutics Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aileron Therapeutics stock.
View analyst ratings for Aileron Therapeutics or view top-rated stocks.

Wall Street analysts have given Aileron Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aileron Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for Aileron Therapeutics.

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its earnings results on Tuesday, August, 10th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01.
View Aileron Therapeutics' earnings history.

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALRN stock has increased by 172.9% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19.

2 analysts have issued 12-month price targets for Aileron Therapeutics' shares. Their forecasts range from $2.00 to $5.00. On average, they expect Aileron Therapeutics' share price to reach $3.50 in the next twelve months. This suggests a possible upside of 218.2% from the stock's current price.
View analysts' price targets for Aileron Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aileron Therapeutics include 89bio (ETNB), Rallybio (RLYB), Evelo Biosciences (EVLO), Rain Therapeutics (RAIN), Aerovate Therapeutics (AVTE), ANI Pharmaceuticals (ANIP), Humanigen (HGEN), Spectrum Pharmaceuticals (SPPI), Antibe Therapeutics (ATBPD), Aeglea BioTherapeutics (AGLE), NexImmune (NEXI), Locust Walk Acquisition (LWAC), ProQR Therapeutics (PRQR), Pieris Pharmaceuticals (PIRS) and Molecular Templates (MTEM).
View all of ALRN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).

(ALRN) raised $61 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Aileron Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.81%), Renaissance Technologies LLC (1.14%), Geode Capital Management LLC (0.85%), Blair William & Co. IL (0.76%), Boothbay Fund Management LLC (0.43%) and State Street Corp (0.08%). Company insiders that own Aileron Therapeutics stock include Jeffrey Allen Bailey, Muneer A Satter, Reinhard J Ambros and Rickenbach Josef H Von.
View institutional ownership trends for Aileron Therapeutics.

ALRN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., and Citadel Advisors LLC.
View insider buying and selling activity for Aileron Therapeutics or view top insider-selling stocks.

ALRN stock was acquired by a variety of institutional investors in the last quarter, including Blair William & Co. IL, Geode Capital Management LLC, State Street Corp, Millennium Management LLC, Boothbay Fund Management LLC, Morgan Stanley, Morgan Stanley, and Envestnet Asset Management Inc.. Company insiders that have bought Aileron Therapeutics stock in the last two years include Jeffrey Allen Bailey, Muneer A Satter, Reinhard J Ambros, and Rickenbach Josef H Von.
View insider buying and selling activity for Aileron Therapeutics or or view top insider-buying stocks.

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALRN stock can currently be purchased for approximately $1.10.

Aileron Therapeutics has a market capitalization of $99.61 million. The company earns $-21,160,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Aileron Therapeutics employs 8 workers across the globe.

The official website for Aileron Therapeutics is www.aileronrx.com.

Aileron Therapeutics is headquartered at 490 Arsenal Way, Watertown MA, 02472.

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected].